オプションチェーンは、Achilles Therapeuticsの株式オプションの主要データを様々な行使価格と満期日で表示します。トレーダーはこの情報を使用して、潜在的な取引を分析し、Achilles Therapeuticsの市場センチメントを評価します。.

Achilles Therapeutics (NASDAQ:ACHL) 株価情報, オプションチェーン

Achilles Therapeutics

Achilles Therapeutics PLC is a biopharmaceutical company. It is developing AI-powered precision T-cell therapies targeting clonal neoantigens to treat solid tumors. The company has two ongoing trials, the CHIRON trial in patients with non-small-cell lung cancer and the THETIS trial in patients with recurrent or metastatic melanoma.

Achilles Therapeutics plc - American Depositary Shares

Achilles Therapeutics PLC

DraftKings Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DKNG#NASDAQ">DKNG</a>) reported fourth-quarter revenue of $1.39 billion, missing analyst estimates of $1.43 billion, according to <a href="http://pro.benzinga.com">Benzinga Pro</a>. 
The sports betting company <a href="https://www.benzinga.com/pressreleases/25/02/g43712703/draftkings-reports-fourth-quarter-and-fiscal-year-2024-results">reported</a> fourth-quarter adjusted earnings of 14 cents per share, beating analyst estimates for a loss of 15 cents per share.
Total revenue was up 13% on a year-over-year basis, driven primarily by continued customer engagement, efficient acquisition of new customers, the expansion of the company&#8217;s sportsbook offering into new jurisdictions, higher structural sportsbook hold percentage and the <a href="https://www.benzinga.com/general/sports-betting/24/02/37239149/exclusive-draftkings-partnership-with-barstool-sports-getting-the-band-together-ceo-says-h">acquisition of Jackpocket</a>.
Monthly unique payers jumped 36% year-over-year to 4.8 million. Average revenue per monthly unique payer totaled $97 in the quarter, down 16% year-over-year. DraftKings ended the period with $788 million in cash and cash equivalents.
&#8220;We continued to efficiently acquire and engage customers, expand structural sportsbook hold percentage and optimize promotional reinvestment in fiscal year 2024, while we simultaneously experienced customer-friendly sport outcomes,&#8221; said Jason Robins,&nbsp;co-founder and CEO of DraftKings.
&#8220;Looking ahead to 2025 and beyond, I am excited to further enhance our customer economics through new initiatives such as extending our lead in live betting and advancing cross sell efforts to and from new verticals. Our focus remains on driving sustainable growth in revenue and profitability.&#8221;
See Also: <a href="https://www.benzinga.com/25/02/43608426/super-bowl-lix-rematch-again-sportsbooks-list-eagles-chiefs-as-top-favorites-for-super-bowl-lx">Super Bowl LIX Rematch Again? Sportsbooks List Eagles, Chiefs As Top Favorites For Super Bowl LX</a>
Outlook: DraftKings raised its full-year 2025 revenue guidance to a range of $6.3 billion to $6.6 billion, up from a prior range of $6.2 billion to $6.6 billion, representing approximately 35% year-over-year growth. Analysts are anticipating full-year revenue of $6.4 billion, according to <a href="http://pro.benzinga.com">Benzinga Pro</a>. The company continues to expect full-year adjusted EBITDA of $900 million to $1 billion.
DraftKings noted that it&#8217;s live with mobile sports betting in 25 states and with iGaming in five states. The company expects to launch its sportsbook in Missouri after voters passed a legalized sports betting initiative in November. DraftKings also expects to launch its sportsbook in Puerto Rico, pending market access and regulatory approvals.
DraftKings executives will further discuss the company&#8217;s quarterly results on a conference call set for 5 p.m. ET.
Price Action: <a href="http://benzinga.com/quote/dkng">DraftKings shares</a> were up nearly 25% year-to-date heading into the print. The stock was up 5.5% after hours, trading at $49 at the time of publication, according to <a href="http://pro.benzinga.com">Benzinga Pro</a>.
Photo: courtesy of DraftKings.

Earnings

News

Sports Betting

Guidance

Movers

General

DKNG

DraftKings Q4 Earnings: Revenue Miss, EPS Beat, Monthly Uniques Up 36% YoY, Raised Guidance And More

Franklin BSP Realty Trust (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FBRT#NYSE">FBRT</a>) reported quarterly earnings of $0.30 per share which beat the analyst consensus estimate of $0.29 by 3.45 percent. This is a 23.08 percent decrease over earnings of $0.39 per share from the same period last year. The company reported quarterly sales of $55.95 million which beat the analyst consensus estimate of $50.89 million by 9.94 percent. This is a 2.17 percent increase over sales of $54.76 million the same period last year.

Earnings Beats

FBRT

Franklin BSP Realty Trust Q4 Adj $0.30 Beats $0.29 Estimate, Sales $55.95M Beat $50.89M Estimate

Offerings

APTO

Aptose Enters $25M Committed Equity Facility And Enters At-the-Market Distributions

Dividends

MUSA

Murphy Increases Quarterly Dividend From $0.48 To $0.49

WIIM

Cooper-Standard Holdings shares are trading lower following soft guidance.

Outset Medical Notified By FDA That All Issues Cited In Jul. 2023 Warning Letter Have Been Addressed

Precision Optics Corp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/POCI#NASDAQ">POCI</a>) reported quarterly losses of $(0.15) per share. This is a 15.38 percent decrease over losses of $(0.13) per share from the same period last year. The company reported $4.53 million in sales this quarter. This is a 6.16 percent decrease over sales of $4.82 million the same period last year.

POCI

Precision Optics Corp Q2 EPS $(0.15) Down From $(0.13) YoY, Sales $4.53M Down From $4.82M YoY

Lamb Weston Holdings, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LW#NYSE">LW</a>) announced today that it has received notice of an unsolicited "mini-tender" offer by TRC Capital Investment Corporation (TRC) dated February 11, 2025, to purchase up to 2,000,000 shares of Lamb Weston's common stock at a price of $55.95 per share in cash. TRC's offer price of $55.95 per share is approximately 4.34% lower than the $58.49 closing share price of Lamb Weston's common stock on February 10, 2025, the business day prior to the date of the offer. The offer represents approximately 1.4% of Lamb Weston's outstanding common stock as of that date.
Lamb Weston does not endorse TRC's unsolicited offer or the offer documentation. Lamb Weston is not affiliated with or associated in any way with TRC, its mini-tender offer or its offer documentation.

Management

Lamb Weston Responds To TRC Capital's "Mini-Tender" Offer To Purchase Up To 2M Shares Of Common Stock For A Price Of $55.95/Share; Says Lamb Weston Does Not Endorse TRC's Unsolicited Offer Or The Offer Documentation

FROG

JFrog shares are trading higher after the company reported better-than-expected Q4 financial results and issued FY25 adjusted EPS guidance above its estimate.

GameStop shares are trading higher following a CNBC report suggesting that the company is considering investing in Bitcoin and other cryptocurrencies.

NPCE

Neuropace Announces That It Intends To Offer And Sell, In An Underwritten Public Offering, $65M Of Shares Of Its Common Stock

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

Markets

CNBC: 'GameStop is considering investing in bitcoin and other cryptocurrencies, sources say'

Buybacks

Tennant Authorizes A New Share Repurchase Program Of Up To 2M Shares Of The Company's Common Stock, Effective February 11, 2025

LGCY

Legacy Education shares are trading lower. The company reported Q2 financial results.

ICooper-Standard  Says 'Industry projections anticipate global light vehicle production will be lower in 2025 compared to 2024. Inflationary headwinds are expected to continue.'

Bowman Consulting Group Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BWMN#NASDAQ">BWMN</a>), a national engineering services firm offering infrastructure, technology and program management solutions, has been awarded a four-year contract to provide on-call engineering design services for the University of New Mexico (UNM) with a total aggregate cap of $7.5 million.
Under the multi-year agreement, Bowman may provide surveying, civil engineering and subsurface utility engineering (SUE) services across UNM's extensive network of campuses, medical facilities, research hubs and academic institutions. These include UNM's Central and Branch campuses, UNM Hospital, the UNM Science &amp; Technology Park, South Campus, the UNM Comprehensive Cancer Center and the UNM Health Sciences Center. Bowman's expertise in these disciplines will support campus expansion, facility upgrades and long-term infrastructure planning.

Contracts

BWMN

Bowman Secures 4-Year ~$7.5M Contract To Provide Engineering Design Services For The University Of New Mexico

Cooper-Standard Sees FY25 Revenue $2.7B-$2.8B vs. $3.00B Est.

Piedmont Office Realty (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PDM#NYSE">PDM</a>) is looking for FY2025 FFO of $1.38-$1.44 vs $1.46 analyst estimate..

Piedmont Office Realty Sees FY2025 FFO $1.38-$1.44 vs $1.46 Est

ORRF

Orrstown Financial Services Announces That Adam L. Metz Has Been Promoted To Senior Executive Vice President And Chief Operating Officer Of The Company And Its Subsidiary Bank, Orrstown Bank. Will Succeed Thomas R. Quinn, Jr. As President And Chief Executive Officer Of The Company And The Bank Upon Mr. Quinn's Retirement On May 25, 2026.

IFRX

InflaRx shares are trading lower after the company announced a public offering, the size or amount not disclosed.

Achilles Therapeutics (ACHL) has released an update. Achilles Therapeutics has halted its TIL-based cNeT therapy development and is closing its CHI...

Achilles Therapeutics Shifts Strategy, Seeks Alternatives

Achilles climbs after decision to find strategic alternatives

Achilles Therapeutics GAAP EPS of -$0.48

Achilles Therapeutics (ACHL) has released an update. Achilles Therapeutics has reported a cash position of $86.1 million as of September 30, 2024, ...

Achilles Therapeutics Explores Strategic Options Amid Financial Update

Achilles Therapeutics Plc ( ($ACHL) ) has released its Q3 earnings. Here is a breakdown of the information Achilles Therapeutics Plc presented to i...

Achilles Therapeutics Reports Q3 2024 Financial Results

Achilles Therapeutics (ACHL) has released an update. Achilles Therapeutics has successfully regained compliance with Nasdaq's minimum bid price req...

Achilles Therapeutics Regains Nasdaq Compliance, Boosting Investor Confidence

Achilles Therapeutics (ACHL) announced that it has transferred the commercial license of data and samples from the TRACERx Non-Small Cell Lung Canc...

Achilles Therapeutics sells technology assets to AstraZeneca for $12M

Achilles Therapeutics sells technology assets to AstraZeneca

Achilles Therapeutics ( ($ACHL) ) just unveiled an update. Achilles Therapeutics has sold its technology assets, including data and samples from th...

Achilles Therapeutics Sells Technology Assets to AstraZeneca for $12 Million

The latest announcement is out from Achilles Therapeutics ( ($ACHL) ). Achilles Therapeutics announced the resignation of three members from its Bo...

Achilles Therapeutics Announces Board Resignations Amid Strategic Realignment

ACHL

AZNCF

Health Care

Press Releases

Achilles Therapeutics Provides Interim Phase I/IIa Update on Clonal Neoantigen Reactive T Cells in Advanced NSCLC and Melanoma Including First Patients Dosed with Enhanced Host Conditioning

Achilles Therapeutics Reports Fourth Quarter and Year-End 2023 Financial Results and Recent Business Highlights

Achilles Therapeutics Reports First Quarter 2024 Financial Results and Recent Business Highlights

Achilles Therapeutics Receives Nasdaq Deficiency Notice Regarding Minimum Bid Price Requirement

Achilles Therapeutics Announces Research Collaboration with Arcturus Therapeutics to Explore Second-Generation Personalized mRNA Cancer Vaccines

Achilles Therapeutics Reports Second Quarter 2024 Financial Results and Recent Business Updates

Comments

Achilles Therapeutics

Achilles Therapeutics (ACHL) オプション

No option chain data available. Please try again later

ニュース

パートナーシップ

ベンジンガ・グローバル